100 related articles for article (PubMed ID: 32054861)
1. A case report of multiple primary prostate tumors with differential drug sensitivity.
Wilkinson S; Harmon SA; Terrigino NT; Karzai F; Pinto PA; Madan RA; VanderWeele DJ; Lake R; Atway R; Bright JR; Carrabba NV; Trostel SY; Lis RT; Chun G; Gulley JL; Merino MJ; Choyke PL; Ye H; Dahut WL; Turkbey B; Sowalsky AG
Nat Commun; 2020 Feb; 11(1):837. PubMed ID: 32054861
[TBL] [Abstract][Full Text] [Related]
2. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
[TBL] [Abstract][Full Text] [Related]
3. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
4. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer.
Martin PL; Yin JJ; Seng V; Casey O; Corey E; Morrissey C; Simpson RM; Kelly K
Oncogene; 2017 Jan; 36(4):525-533. PubMed ID: 27375016
[TBL] [Abstract][Full Text] [Related]
6. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
Ku SY; Rosario S; Wang Y; Mu P; Seshadri M; Goodrich ZW; Goodrich MM; Labbé DP; Gomez EC; Wang J; Long HW; Xu B; Brown M; Loda M; Sawyers CL; Ellis L; Goodrich DW
Science; 2017 Jan; 355(6320):78-83. PubMed ID: 28059767
[TBL] [Abstract][Full Text] [Related]
7. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
[TBL] [Abstract][Full Text] [Related]
9. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes
van de Ven AL; Tangutoori S; Baldwin P; Qiao J; Gharagouzloo C; Seitzer N; Clohessy JG; Makrigiorgos GM; Cormack R; Pandolfi PP; Sridhar S
Mol Cancer Ther; 2017 Jul; 16(7):1279-1289. PubMed ID: 28500233
[TBL] [Abstract][Full Text] [Related]
10. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
11. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathology of prostate cancer].
Tímár J
Magy Onkol; 2019 Mar; 63(1):5-9. PubMed ID: 30889615
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer: towards appropriate use of androgen deprivation therapy.
Shahinian VB
Nat Rev Urol; 2013 Apr; 10(4):192-3. PubMed ID: 23419490
[No Abstract] [Full Text] [Related]
14. Understanding heterogeneity of treatment effect in prostate cancer.
Aly A; Mullins CD; Hussain A
Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
[TBL] [Abstract][Full Text] [Related]
15. [First case of complete genomic sequencing in prostate cancer].
Pene F; Toledano A; Laabidi M
Prog Urol; 2014 Dec; 24(16):1041-2. PubMed ID: 25288584
[No Abstract] [Full Text] [Related]
16. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
17. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
18. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
19. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
20. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]